Lucyd (LUCY) Fundamentals 2026 — Revenue Analysis | SniperIQ
Lucyd (LUCY) is a US-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of
Lucyd (LUCY) has a market capitalization of approximately
Lucyd's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Lucyd runs a net profit margin of -272.5%, a gross margin of 17.5%, and an operating margin of -300.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Lucyd reported revenue of
Lucyd does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Lucyd carries a debt-to-equity ratio of 0.01x and a current ratio of 8.02x, with a market beta of 2.70. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Lucyd (LUCY) the key facts are: market cap
Get Lucyd's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.